Coya Tapia
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PloS one 2015; 10:e0123435.
Apr 17, 2015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Apr 17, 2015PloS one 2015; 10:e0123435
Varga Zsuzsanna, Cassoly Estelle, Li Qiyu, Öhlschlegel Christian, Tapia Coya, Lehr Hans Anton, Klingbiel Dirk, Thürlimann Beat, Ruhstaller Thomas
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
Varga Z, Viale G, Mastropasqua M, Wagner U, Tapia C, Singer G, Schreiber-Facklam H, Schobinger-Clement S, Sancho Oliver S, Rakozy C, Padberg B, Öhlschlegel C, Obermann E, Noske A, Kaup D, Frick H, Dommann-Scherrer C, Diebold J, Lehr H. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PloS one 2012; 7:e37379.
May 25, 2012How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
May 25, 2012PloS one 2012; 7:e37379
Varga Zsuzsanna, Viale Giuseppe, Mastropasqua Mauro G, Wagner Urs, Tapia Coya, Singer Gad, Schreiber-Facklam Heide, Schobinger-Clement Sylviane, Sancho Oliver Sara, Rakozy Christiane, Padberg Barbara, Öhlschlegel Christian, Obermann Ellen, Noske Aurelia, Kaup Daniela, Frick Harald, Dommann-Scherrer Corina, Diebold Joachim, Lehr Hans-Anton
Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Tapia C, Glatz K, Obermann E, Grilli B, Barascud A, Herzog M, Schönegg R, Savic S, Bubendorf L. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathol 2011; 119:404-10.
Jul 5, 2011Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Jul 5, 2011Cancer Cytopathol 2011; 119:404-10
Tapia Coya, Glatz Kathrina, Obermann Ellen C, Grilli Bruno, Barascud Audrey, Herzog Michelle, Schönegg René, Savic Spasenija, Bubendorf Lukas
HER2 gene status in primary breast cancers and matched distant metastases
Tapia C, Feichter G, Terracciano L, Cathomas G, Zlobec I, Barascud A, Herzog M, Grilli B, Novotny H, Schönegg R, Wagner U, Savic S, Bubendorf L. HER2 gene status in primary breast cancers and matched distant metastases. Breast cancer research : BCR 2007; 9:R31.
Jan 1, 2007HER2 gene status in primary breast cancers and matched distant metastases
Jan 1, 2007Breast cancer research : BCR 2007; 9:R31
Tapia Coya, Feichter Georg, Terracciano Luigi, Cathomas Gieri, Zlobec Inti, Barascud Audrey Devito, Herzog Michelle, Grilli Bruno, Novotny Hedvika, Schönegg René, Wagner Urs, Savic Spasenija, Bubendorf Lukas